<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945580</url>
  </required_header>
  <id_info>
    <org_study_id>U9920</org_study_id>
    <secondary_id>AUGS PFD Outcome Registry</secondary_id>
    <nct_id>NCT01945580</nct_id>
  </id_info>
  <brief_title>Xenform Postmarket Surveillance Study</brief_title>
  <acronym>Xenform</acronym>
  <official_title>A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TEI Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare transvaginal repair with a biologic mesh to traditional native tissue repair in
      women surgically treated for anterior/apical pelvic organ prolapse with or without
      concurrent cystocele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate clinical effectiveness of transvaginal repair with
      Xenform against traditional native tissue repair in women surgically treated for
      anterior/apical pelvic organ prolapse with or without concurrent cystocele.  Secondary
      objectives are to evaluate Xenform-related complications and subject reported outcomes.

      The primary endpoint of the study is to achieve non-inferiority of transvaginal repair with
      Xenform over native tissue repair at 36 months as compared to baseline. Success will be
      based on a composite of objective and subjective measures.

      Additionally, a co-primary endpoint of the study is to achieve non-inferiority of
      transvaginal repair with Xenform to native tissue repair for safety by comparing rates of
      serious device or serious procedure related complications between baseline and the 36 month
      time point.

      The secondary endpoints of the study include assessments of complications and subject
      reported outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Surgical Success</measure>
    <time_frame>36 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Surgical success will be measured based on anatomic success measures (leading edge of prolapse is at or above the hymen and/or POPQ measurements), no additional surgical treatment for pelvic organ prolapse in the anterior/apical vaginal compartments, and patient denies symptoms of vaginal bulging (per PFDI-20 questionnaire).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>36 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of mesh erosion, mesh exposure, de novo dyspareunia, and the following device or procedure related events: pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding dysfunction.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">454</enrollment>
  <condition>Anterior and Apical Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Xenform</arm_group_label>
    <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Prolapse Repair with Native Tissue Only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prolapse Repair</intervention_name>
    <description>Transvaginal anterior/apical pelvic organ prolapse repair</description>
    <arm_group_label>Xenform</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Transvaginal</other_name>
    <other_name>Prolapse</other_name>
    <other_name>POP Repair</other_name>
    <other_name>Anterior</other_name>
    <other_name>Apical</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with pelvic organ prolapse at or beyond the hymen who will be treated surgically.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is female

          -  Subject is at least 18 years of age

          -  Subject has pelvic organ prolapse with the leading edge at or beyond the hymen.  At
             or beyond the hymen is defined as POP-Q scores of Ba≥0 or C≥0 (for prolapse of the
             apical compartment alone) or C≥-1/2 TVL (for a multi-compartment prolapse that
             includes the apical compartment).

          -  Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3,
             response of 2 or higher (i.e., responses of &quot;somewhat&quot;, &quot;moderately&quot;, or &quot;quite a
             bit&quot;)

          -  Subject or subject's legally authorized representative is willing to provide written
             informed consent

          -  Subject is willing and able to comply with the follow-up regimen

        Exclusion Criteria:

          -  Subject is pregnant or intends to become pregnant during the study

          -  Subject has an active or chronic systemic infection including any gynecologic
             infection, untreated urinary tract infection (UTI) or tissue necrosis

          -  Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder,
             colo-rectal or cervical)

          -  Subject has had prior or is currently undergoing radiation, laser therapy, or
             chemotherapy in the pelvic area

          -  Subject has taken systemic steroids (within the last month), or immunosuppressive or
             immunomodulatory treatment (within the last 3 months)

          -  Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus
             erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis,
             polymyalgia rheumatica)

          -  Subject has chronic systemic pain that includes the pelvic area or chronic focal pain
             that involves the pelvis

          -  Subject has uncontrolled diabetes mellitus (DM)

          -  Subject has a known neurologic or medical condition affecting bladder function (e.g.,
             multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)

          -  Subject is seeking obliterative vaginal surgery as treatment for pelvic organ
             prolapse (colpocleisis)

          -  Subject is not able to conform to the modified dorsal lithotomy position

          -  Subject is currently participating in or plans to participate in another device or
             drug study during this study

          -  Subject has a known sensitivity to any Xenform component

          -  Subject has had previous prolapse repair with mesh in the target compartment

          -  Subject is planning to undergo a concomitant prolapse repair with use of mesh in the
             non-target compartment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rosenblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Auburn Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Kirkemo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa LeBlanc</last_name>
    <phone>508-683-6636</phone>
    <email>lisa.leblanc@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwest Urology Associates</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Reiter</last_name>
      <phone>714-456-8564</phone>
    </contact>
    <investigator>
      <last_name>Felicia Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente ObGyn Urogynecology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gisselle Zazueta-Damian</last_name>
      <phone>619-221-6274</phone>
    </contact>
    <investigator>
      <last_name>Karl Luber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lizabeth Roper</last_name>
      <phone>860-545-1964</phone>
      <email>Lizabeth.Roper@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Adam Steinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Anne Park</last_name>
      <phone>706-721-0193</phone>
    </contact>
    <investigator>
      <last_name>Brent Parnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cherokee Womens Health</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angel Bobo</last_name>
      <phone>770-720-7733</phone>
    </contact>
    <investigator>
      <last_name>Michael Litrel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Wasielewski</last_name>
      <phone>224-251-3493</phone>
      <email>rwsielewski@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Sylvia Botros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Legion Hospital</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Breaux</last_name>
      <phone>337-783-3222</phone>
    </contact>
    <investigator>
      <last_name>John Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Michaels</last_name>
      <phone>443-471-5753</phone>
    </contact>
    <investigator>
      <last_name>Kaiser Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Acra</last_name>
      <phone>443-471-5750</phone>
      <email>racra@cua.md</email>
    </contact>
    <investigator>
      <last_name>Andrew Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Urogynecology Associates</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Rogers</last_name>
      <phone>617-354-4552</phone>
    </contact>
    <investigator>
      <last_name>Peter Rosenblatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Female Pelvic Medicine &amp; Urogynecology Institute of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>45903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Rogers</last_name>
      <phone>616-588-1135</phone>
      <email>BRogers@grwh.org</email>
    </contact>
    <investigator>
      <last_name>Douglas Van Drie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucy Wright Pelletier</last_name>
      <phone>269-372-7800</phone>
    </contact>
    <investigator>
      <last_name>Roger Beyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Jersey Regional Health</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Wilezol</last_name>
      <phone>856-641-8000</phone>
    </contact>
    <investigator>
      <last_name>Gary Mirone, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Urogynecology</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunda Simpkins</last_name>
      <phone>856-968-7547</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Caraballo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Stein</last_name>
      <phone>716-888-4859</phone>
      <email>mstein3@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Tova Ablove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Greene</last_name>
      <phone>212-746-0570</phone>
      <email>cag9060@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Renuka Tyagi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Mantor</last_name>
      <phone>646-825-6328</phone>
      <email>laurie.mantor@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Scott Smilen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Spuma</last_name>
      <phone>212-844-6239</phone>
    </contact>
    <investigator>
      <last_name>Sovrin Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betty Rupp</last_name>
      <phone>919-843-8114</phone>
      <email>brupp@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Matthews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Jester</last_name>
      <phone>336-765-9350</phone>
    </contact>
    <investigator>
      <last_name>Bradley Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prime Care of SEO</name>
      <address>
        <city>Dresden</city>
        <state>Ohio</state>
        <zip>43821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Campbell</last_name>
      <phone>740-455-7640</phone>
    </contact>
    <investigator>
      <last_name>Mitesh Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Moore</last_name>
      <phone>864-455-6203</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Garris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Urogynecology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Miller</last_name>
      <phone>803-457-7000</phone>
    </contact>
    <investigator>
      <last_name>Andrea Pezzella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Cisnero</last_name>
      <phone>713-790-9779</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Colinas ObGyn</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Saldana</last_name>
      <phone>972-257-5300</phone>
    </contact>
    <investigator>
      <last_name>John Zavaleta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Research Foundation</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Kennedy</last_name>
      <phone>432-368-6950</phone>
    </contact>
    <investigator>
      <last_name>Pill Raja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Medical Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Richmond</last_name>
      <phone>425-228-0722</phone>
    </contact>
    <investigator>
      <last_name>James Rice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wheaton Franciscan St. Luke's Women's Health Pavilion</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>September 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POP</keyword>
  <keyword>Transvaginal</keyword>
  <keyword>Native Tissue Repair</keyword>
  <keyword>Repair Augmented with Mesh</keyword>
  <keyword>Biologic Graft</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
